These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28274526)

  • 1. Efficacy of long-term omalizumab therapy in patients with severe asthma.
    Saji J; Yamamoto T; Arai M; Mineshita M; Miyazawa T
    Respir Investig; 2017 Mar; 55(2):114-120. PubMed ID: 28274526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of omalizumab in patients with severe asthma using the asthma health questionnaire and asthma control test].
    Saji J; Arai M; Yamamoto T; Mineshita M; Miyazawa T
    Arerugi; 2014 Dec; 63(10):1338-47. PubMed ID: 25634459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
    Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
    J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.
    Gouder C; West LM; Montefort S
    Int J Clin Pharm; 2015 Feb; 37(1):36-43. PubMed ID: 25394832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
    Weheba IM; Abdelsayed AM; Arnaout RK; Zeitouni MO; Mobaireek KF; AlHarthi TB; Mobeireek AF
    Ann Saudi Med; 2018; 38(6):439-444. PubMed ID: 30531179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.
    Kupryś-Lipińska I; Majak P; Molinska J; Kuna P
    BMC Pulm Med; 2016 Apr; 16(1):61. PubMed ID: 27117315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
    Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
    Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ; Singh H; Diaz J; Peters JI
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab in non-allergic Asthma: A report of 13 cases.
    Çelebi Sözener Z; Aydın Ö; Mısırlıgil Z; Mungan D; Demirel YS; Çelik GE; Sin BA; Bavbek S
    J Asthma; 2018 Jul; 55(7):756-763. PubMed ID: 28800272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.
    Luu M; Bardou M; Bonniaud P; Goirand F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1503-1511. PubMed ID: 27748630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
    Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.